Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Aging in Fabry Disease: Role of Telomere Length, Telomerase Activity, and Kidney Disease.

Cokan Vujkovac A, Novaković S, Vujkovac B, Števanec M, Škerl P, Šabovič M.

Nephron. 2019 Sep 11:1-9. doi: 10.1159/000502909. [Epub ahead of print]

PMID:
31509825
2.

Fabry disease: diagnostic methods in nephrology practice.

Vujkovac B.

Clin Nephrol. 2017 Supplement 1;88(13):44-47. doi: 10.5414/CNP88FX28.

PMID:
28601129
3.

Paricalcitol as an Antiproteinuric Agent Can Result in the Deterioration of Renal and Heart Function in a Patient with Fabry Disease.

Keber T, Tretjak M, Cokan Vujkovac A, Mravljak M, Ravber K, Vujkovac B.

Am J Case Rep. 2017 Jun 9;18:644-648.

4.

Renal Replacement Therapy in Slovenia: Excerpts From 2013 Data.

Buturović-Ponikvar J, Gubenšek J, Arnol M, Adamlje T, Ceglar Z, Damevska G, Globokar M, Černe S, Čufer A, Drozg A, Ekart R, Knap B, Kandus A, Kapun S, Kralj-Lopert S, Klančič D, Kunc-Rešek N, Kralj S, Malovrh M, Močivnik M, Novljan G, Romozi K, Rus I, Saksida S, Vujkovac B, Ponikvar R.

Ther Apher Dial. 2016 Jun;20(3):223-8. doi: 10.1111/1744-9987.12427.

PMID:
27312905
5.

Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy.

Warnock DG, Thomas CP, Vujkovac B, Campbell RC, Charrow J, Laney DA, Jackson LL, Wilcox WR, Wanner C.

J Med Genet. 2015 Dec;52(12):860-6. doi: 10.1136/jmedgenet-2015-103471. Epub 2015 Oct 21.

6.

Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease.

Goláň L, Goker-Alpan O, Holida M, Kantola I, Klopotowski M, Kuusisto J, Linhart A, Musial J, Nicholls K, Gonzalez-Rodriguez D, Sharma R, Vujkovac B, Chang P, Wijatyk A.

Drug Des Devel Ther. 2015 Jul 8;9:3435-44. doi: 10.2147/DDDT.S80928. eCollection 2015.

7.

Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document.

Biegstraaten M, Arngrímsson R, Barbey F, Boks L, Cecchi F, Deegan PB, Feldt-Rasmussen U, Geberhiwot T, Germain DP, Hendriksz C, Hughes DA, Kantola I, Karabul N, Lavery C, Linthorst GE, Mehta A, van de Mheen E, Oliveira JP, Parini R, Ramaswami U, Rudnicki M, Serra A, Sommer C, Sunder-Plassmann G, Svarstad E, Sweeb A, Terryn W, Tylki-Szymanska A, Tøndel C, Vujkovac B, Weidemann F, Wijburg FA, Woolfson P, Hollak CE.

Orphanet J Rare Dis. 2015 Mar 27;10:36. doi: 10.1186/s13023-015-0253-6.

8.

Exocrine pancreatic insufficiency is not a cause of abdominal complaints in patients with Fabry disease.

Vujasinovic M, Tepes B, Vujkovac B, Cokan Vujkovac A, Tretjak M, Korat V.

Wien Klin Wochenschr. 2015 Dec;127(23-24):931-4. doi: 10.1007/s00508-015-0731-9. Epub 2015 Apr 3.

PMID:
25835592
9.

Renal replacement therapy in Slovenia: excerpts from 2011 data.

Buturović-Ponikvar J, Gubenšek J, Arnol M, Adamlje T, Blanuša D, Ceglar Z, Steklasa SC, Černe S, Čufer A, Drozg A, Ekart R, Guček A, Kandus A, Kapun S, Kralj-Lopert S, Klančič D, Kunc-Rešek N, Kralj S, Malovrh M, Močivnik M, Novljan G, Ponikvar R, Rus I, Saksida S, Vujkovac B.

Ther Apher Dial. 2013 Aug;17(4):357-62. doi: 10.1111/1744-9987.12078.

PMID:
23931871
10.

Recommendations on reintroduction of agalsidase Beta for patients with fabry disease in europe, following a period of shortage.

Linthorst GE, Burlina AP, Cecchi F, Cox TM, Fletcher JM, Feldt-Rasmussen U, Giugliani R, Hollak CE, Houge G, Hughes D, Kantola I, Lachmann R, Lopez M, Ortiz A, Parini R, Rivera A, Rolfs A, Ramaswami U, Svarstad E, Tondel C, Tylki-Szymanska A, Vujkovac B, Waldek S, West M, Weidemann F, Mehta A.

JIMD Rep. 2013;8:51-6. doi: 10.1007/8904_2012_160. Epub 2012 Jul 14.

11.

Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation.

Warnock DG, Ortiz A, Mauer M, Linthorst GE, Oliveira JP, Serra AL, Maródi L, Mignani R, Vujkovac B, Beitner-Johnson D, Lemay R, Cole JA, Svarstad E, Waldek S, Germain DP, Wanner C; Fabry Registry.

Nephrol Dial Transplant. 2012 Mar;27(3):1042-9. doi: 10.1093/ndt/gfr420. Epub 2011 Jul 29.

12.

Association between platelet-related hemostasis impairment and functional iron deficiency in hemodialysis patients.

Zupan IP, Sabovic M, Salobir B, Ponikvar JB, Cernelc P, Lavre J, Vujkovac B.

Ther Apher Dial. 2011 Feb;15(1):34-9. doi: 10.1111/j.1744-9987.2010.00853.x. Epub 2010 Aug 31.

PMID:
21272250
13.

Urinary total globotriaosylceramide and isoforms to identify women with Fabry disease: a diagnostic test study.

Paschke E, Fauler G, Winkler H, Schlagenhauf A, Plecko B, Erwa W, Breunig F, Urban W, Vujkovac B, Sunder-Plassmann G, Kotanko P.

Am J Kidney Dis. 2011 May;57(5):673-81. doi: 10.1053/j.ajkd.2010.10.046. Epub 2010 Dec 24.

PMID:
21186071
14.

Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry.

Wanner C, Oliveira JP, Ortiz A, Mauer M, Germain DP, Linthorst GE, Serra AL, Maródi L, Mignani R, Cianciaruso B, Vujkovac B, Lemay R, Beitner-Johnson D, Waldek S, Warnock DG.

Clin J Am Soc Nephrol. 2010 Dec;5(12):2220-8. doi: 10.2215/CJN.04340510. Epub 2010 Sep 2.

15.

End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry.

Ortiz A, Cianciaruso B, Cizmarik M, Germain DP, Mignani R, Oliveira JP, Villalobos J, Vujkovac B, Waldek S, Wanner C, Warnock DG.

Nephrol Dial Transplant. 2010 Mar;25(3):769-75. doi: 10.1093/ndt/gfp554. Epub 2009 Oct 21.

PMID:
19846394
16.

Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN).

Fogo AB, Bostad L, Svarstad E, Cook WJ, Moll S, Barbey F, Geldenhuys L, West M, Ferluga D, Vujkovac B, Howie AJ, Burns A, Reeve R, Waldek S, Noël LH, Grünfeld JP, Valbuena C, Oliveira JP, Müller J, Breunig F, Zhang X, Warnock DG; all members of the International Study Group of Fabry Nephropathy (ISGFN).

Nephrol Dial Transplant. 2010 Jul;25(7):2168-77. doi: 10.1093/ndt/gfp528. Epub 2009 Oct 15.

17.
18.

The effect of long-term, low-dose tranexamic acid treatment on platelet dysfunction and haemoglobin levels in haemodialysis patients.

Sabovic M, Zupan IP, Salobir B, Zupan I, Cernelc P, Lavre J, Vujkovac B.

Thromb Haemost. 2005 Dec;94(6):1245-50.

PMID:
16411401
19.

Epoetin responsiveness in peritoneal dialysis patients: a multi-center Slovenian study.

Pajek J, Bucar-Pajek M, Grego K, Gucek A, Bevc S, Ekart R, Vujkovac B, Golob-Kosmina P, Kandus A, Bren AF.

Ther Apher Dial. 2005 Jun;9(3):228-32.

PMID:
15966995
20.

The study of anaemia-related haemostasis impairment in haemodialysis patients by in vitro closure time test.

Zupan IP, Sabovic M, Salobir B, Ponikvar JB, Cernelc P, Lavre J, Vujkovac B.

Thromb Haemost. 2005 Feb;93(2):375-9.

PMID:
15711757
21.

Remarkable variability in renal disease in a large Slovenian family with Fabry disease.

Verovnik F, Benko D, Vujkovac B, Linthorst GE.

Eur J Hum Genet. 2004 Aug;12(8):678-81.

22.

Severe diabetic ketoacidosis associated with acute myocardial necrosis.

Tretjak M, Verovnik F, Vujkovac B, Slemenik-Pusnik C, Noc M.

Diabetes Care. 2003 Oct;26(10):2959-60. No abstract available.

PMID:
14514613
23.

Tranexamic acid is beneficial as adjunctive therapy in treating major upper gastrointestinal bleeding in dialysis patients.

Sabovic M, Lavre J, Vujkovac B.

Nephrol Dial Transplant. 2003 Jul;18(7):1388-91.

PMID:
12808178
24.

Treatment of subdural and intracerebral haematomas in a haemodialysis patient with tranexamic acid.

Vujkovac B, Sabovic M.

Nephrol Dial Transplant. 2000 Jan;15(1):107-9. No abstract available.

PMID:
10607778
25.

Successful treatment of bleeding from colonic angiodysplasias with tranexamic acid in a hemodialysis patient.

Vujkovac B, Lavre J, Sabovic M.

Am J Kidney Dis. 1998 Mar;31(3):536-8.

PMID:
9506694

Supplemental Content

Loading ...
Support Center